IASLC 2021 Hot Topic Meeting: Small Cell Lung Cancer

SCLC 2021 Image
Overview

The fourth biennial IASLC Small Cell Lung Cancer Meeting will be held as a Worldwide Virtual Event in the Fall of 2021. The meeting will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research, including, but not limited to, basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. From its inception, this meeting's goals have been to provide a “state-of-the-state” update on recent progress in small cell lung cancer research, to establish a forward-looking perspective on key unanswered questions in the field, and to promote research collaboration among small cell lung cancer investigators. We hope that you will join us for #SCLC21. Additional meeting information will follow soon.

Related Files
Triparna Sen

Understanding and Targeting SCLC

The main hurdles to finding an effective and sustainable treatment option for SCLC include an incomplete understanding of the biology of the disease, a lack of actionable targets, and the ineffectiveness of or rapid resistance to existing therapies, including immunotherapy.

Date
Oct 29, 2021 -
Oct 30, 2021

Detailed Program

All Times in ET

Opening Ceremony and Keynote 

Presentation 

Start Time

Presenter 

Chairs' Welcome Address  11:00 Charles Rudin and Triparna Sen, Meeting Chairs 
IASLC President Welcome 11:10   Heather Wakelee 
IASLC Membership: Why We Should All be IASLC Members  11:15  Kelsey Wood 
Remembrance for Pierre Massion 11:18  Christine Lovly & Johathan Lehman
Keynote: Lessons from CDX models in SCLC 11:23 Caroline Dive 
Keynote Discussion with Q+A 11:53  

 

All Times in ET

Single Cell Analysis in SCLC 

Presentation  Start Time Presenter
Session Welcome   Caroline Dive, Session Moderator 
Single Cell ATLAS of SCLC 12:22 Joseph Chan
Plasticity of SCLC Subtypes: Lessons from GEMMs   12:34 Trudy Oliver 
Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity 12:46 Lauren Byers
CyTOF of SCLC models  12:54 Jonathan Lehman 
Panel Discussion with Q&A 1:02  

All Times in ET

Omnics in SCLC

Presentation Start Time Presenter
Session Welcome   Trudy Oliver, Session Moderator
Genomic Characterization of SCLC  13:20 Julie George
Systematic Determination of Functional Impacts of Recurrent SCLC Mutations  13:32 Dominic Rothwell 
Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer 13:44 Ramaswamy Govindan
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation 13:56 Triparna Sen 
Panel Discussion with Q&A 14:08  

All Times in ET

Biomarkers/Liquid Biopsy/Metastasis in SCLC

Presentation  Start Time Presenter 
Session Welcome    Christine Lovly 
Small-cell Lung Cancer Brain Metastases Transcriptomics  14:30 Afshin Dowlati
Neddylation in SCLC  14:42 David MacPherson 
Metastasis, Liquid Biopsy, and/or Biomarkers 14:54  
SLFN11 in SCLC 15:06  
Panel Discussion with Q&A  15:18  

All Times in ET

Novel Pathways and Targets in SCLC- Session 1

Presentation  Start Time Presenter
Session Welcome    Lauren Byers, Session Moderator 
Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors 15:40 Ben Lok 
DLL3 15:52 Katie Tully
LSD1-ZFP63L1 in SCLC 16:04 Matt Oser 
Interactions between SCLC and Neurons  16:16 Humsa Venkatesh
Panel Discussion with Q&A 16:28  

All Times in ET

Clinical Trials in SCLC 

Presentation  Start Time Presenter
Session Welcome   Kristin Higgins, Session Moderator 
Analysis of our Investigator-initiated Phase I/II trial Studying Olaparib and Temozolomide in SCLC 16:50 Catherine Meador  
Immunotherapy in SCLC  17:02 Luis Paz-Ares
Inflamed Subtype and its Clinical Implications  17:14 Taofeek Owonikoko
EZH2+irinotecan Clinical Trial  17:26 Victoria Lai
Panel Discussion with Q&A  17:53  

All Times in ET

Closing 

Presentation  Start Time Presenter
Day 1 Closing Message  17:53 Charles Rudin and Triparna Sen, Meeting Chairs 

All Times in ET

Industry Symposium 

Session  Start Time 
October 29 Industry Symposium 18:05 

All Times in ET

Early Career Session (October 30) 

Presentation  Start Time Presenter
Session Welcome    Ben Lok, Moderator
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate   10:00 Abbie Ireland  
XPO1 as a Target for Chemoresistance in SCLC  10:10 Alvaro Quintanal Villalonga 
Methylation  10:20  Francesca Chemi 
CDK7 in SCLC  10:30 Hua Zhang 
B7-H6 Emerges as a Potential Immunotherapy Target in SCLC  10:40 Portia Thomas  
Molecular Subtyping of SCLC CTCs   10:50 Prasad Kopparapu 
Panel Discussion with Q&A  11:00   

All Times in ET

Welcome and Keynote 

Presentation  Start Time Presenter 
Welcome  11:30  Charles Rudin and Triparna Sen, Meeting Chair 
Keynote: Lessons from Mouse Models 11:35 Julien Sage
Keynote Discussion with Q&A 11:55  

All Times in ET

Subtypes/ Biomarkers in SCLC 

Presentation  Start Time Presenter
Session Welcome   Jane Johnson, Session Moderator 
SCLC Subgroups and Their Potential Clinical Significance   12:10 Carl Gay  
Whole Genome Methylation Analysis of LS-SCLC Samples Reveals Distinct Subtype-Specific Patterns  12:22  
 Histological Subtyping of SCLC SCLC Biomarkers for Lung Cancer Screening  12:34 Natasha Rekhtman
SCLC Biomarkers for Lung Cancer Screening  12:46 Samir Hanash
Panel Discussion with Q&A 12:58  

All Times in ET

Novel Pathways and Targets in SCLC - Session 2 

Presentation  Start Time Presenter
Session Welcome   JT Poirier, Session Moderator 
Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress  13:20  Anish Thomas 
Molecular Subtyping of Primary SCLC Tumors and the Associations between Molecular Subtypes and Therapeutic Biomarkers  13:32 Haobin Chen
Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer 13:44  Ralph Deberardinis
Ferroptosis in SCLC 13:56 Siliva Von Karstedt 
Panel Discussion with Q&A  14:08   

All Times in ET

Mouse Models (Xenografts and GEMMs)

Presentation  Start Time Presenter
Session Welcome    Roman Thomas, Session Moderator 
Metastasis in SCLC 14:30  Arnaud Augert 
Chemoresistance and co Clinical Trials  14:42 Ben Drapkin 
Uncovering Chemoradiation Resistance Mechanisms in Limited Stage SCLC using a paired PDX-PDO-ODX Platform 14:54 Christine Hann 
GEMM of LUAD to SCLC  15:06  Eric Gardner
Panel Discussion with Q&A  15:18  

All Times in ET

 Immunotherapy Approaches in SCLC 

Presentation  Start Time Presenter 
Session Welcome   Ticiana Leal, Session Moderator 
EZH2 in SCLC  15:40  David Barbie 
NK cells in SCLC   15:52 Kate Sutherland
Anti-tumor and Immunological Effects of CDK Inhibitors in SCLC  16:04  Kwok Wong
Examining Predictors of Response to Immune Checkpoint Blockade in SCLC 16:16  Nitin Roper
Panel Discussion with Q&A  16:28   

All Times in ET

Day Two Closing 

Presentation  Start Time Presenter
Closing Message 16:50  Charles Rudin and Triparna Sen, Meeting Chairs

 

All Times in ET

Industry Symposium 

Session Start Time 
October 30 Industry Symposium 17:05 

All Times in ET

Opening Ceremony and Keynote 

Presentation 

Start Time

Presenter 

Chairs' Welcome Address  11:00 Charles Rudin and Triparna Sen, Meeting Chairs 
IASLC President Welcome 11:10   Heather Wakelee 
IASLC Membership: Why We Should All be IASLC Members  11:15  Kelsey Wood 
Remembrance for Pierre Massion 11:18  Christine Lovly & Johathan Lehman
Keynote: Lessons from CDX models in SCLC 11:23 Caroline Dive 
Keynote Discussion with Q+A 11:53  

 

All Times in ET

Single Cell Analysis in SCLC 

Presentation  Start Time Presenter
Session Welcome   Caroline Dive, Session Moderator 
Single Cell ATLAS of SCLC 12:22 Joseph Chan
Plasticity of SCLC Subtypes: Lessons from GEMMs   12:34 Trudy Oliver 
Translating SCLC Molecular Subtypes into Clinical Practice: Opportunities for Precision Medicine and the Challenge of Plasticity 12:46 Lauren Byers
CyTOF of SCLC models  12:54 Jonathan Lehman 
Panel Discussion with Q&A 1:02  

All Times in ET

Omnics in SCLC

Presentation Start Time Presenter
Session Welcome   Trudy Oliver, Session Moderator
Genomic Characterization of SCLC  13:20 Julie George
Systematic Determination of Functional Impacts of Recurrent SCLC Mutations  13:32 Dominic Rothwell 
Recurrent WNT Pathway Alterations are Frequent in Relapsed Small-cell Lung Cancer 13:44 Ramaswamy Govindan
Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation 13:56 Triparna Sen 
Panel Discussion with Q&A 14:08  

All Times in ET

Biomarkers/Liquid Biopsy/Metastasis in SCLC

Presentation  Start Time Presenter 
Session Welcome    Christine Lovly 
Small-cell Lung Cancer Brain Metastases Transcriptomics  14:30 Afshin Dowlati
Neddylation in SCLC  14:42 David MacPherson 
Metastasis, Liquid Biopsy, and/or Biomarkers 14:54  
SLFN11 in SCLC 15:06  
Panel Discussion with Q&A  15:18  

All Times in ET

Novel Pathways and Targets in SCLC- Session 1

Presentation  Start Time Presenter
Session Welcome    Lauren Byers, Session Moderator 
Immunogenic Radiosensitization of SCLC with DNA Repair Inhibitors 15:40 Ben Lok 
DLL3 15:52 Katie Tully
LSD1-ZFP63L1 in SCLC 16:04 Matt Oser 
Interactions between SCLC and Neurons  16:16 Humsa Venkatesh
Panel Discussion with Q&A 16:28  

All Times in ET

Clinical Trials in SCLC 

Presentation  Start Time Presenter
Session Welcome   Kristin Higgins, Session Moderator 
Analysis of our Investigator-initiated Phase I/II trial Studying Olaparib and Temozolomide in SCLC 16:50 Catherine Meador  
Immunotherapy in SCLC  17:02 Luis Paz-Ares
Inflamed Subtype and its Clinical Implications  17:14 Taofeek Owonikoko
EZH2+irinotecan Clinical Trial  17:26 Victoria Lai
Panel Discussion with Q&A  17:53  

All Times in ET

Closing 

Presentation  Start Time Presenter
Day 1 Closing Message  17:53 Charles Rudin and Triparna Sen, Meeting Chairs 

All Times in ET

Industry Symposium 

Session  Start Time 
October 29 Industry Symposium 18:05 

All Times in ET

Early Career Session (October 30) 

Presentation  Start Time Presenter
Session Welcome    Ben Lok, Moderator
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate   10:00 Abbie Ireland  
XPO1 as a Target for Chemoresistance in SCLC  10:10 Alvaro Quintanal Villalonga 
Methylation  10:20  Francesca Chemi 
CDK7 in SCLC  10:30 Hua Zhang 
B7-H6 Emerges as a Potential Immunotherapy Target in SCLC  10:40 Portia Thomas  
Molecular Subtyping of SCLC CTCs   10:50 Prasad Kopparapu 
Panel Discussion with Q&A  11:00   

All Times in ET

Welcome and Keynote 

Presentation  Start Time Presenter 
Welcome  11:30  Charles Rudin and Triparna Sen, Meeting Chair 
Keynote: Lessons from Mouse Models 11:35 Julien Sage
Keynote Discussion with Q&A 11:55  

All Times in ET

Subtypes/ Biomarkers in SCLC 

Presentation  Start Time Presenter
Session Welcome   Jane Johnson, Session Moderator 
SCLC Subgroups and Their Potential Clinical Significance   12:10 Carl Gay  
Whole Genome Methylation Analysis of LS-SCLC Samples Reveals Distinct Subtype-Specific Patterns  12:22  
 Histological Subtyping of SCLC SCLC Biomarkers for Lung Cancer Screening  12:34 Natasha Rekhtman
SCLC Biomarkers for Lung Cancer Screening  12:46 Samir Hanash
Panel Discussion with Q&A 12:58  

All Times in ET

Novel Pathways and Targets in SCLC - Session 2 

Presentation  Start Time Presenter
Session Welcome   JT Poirier, Session Moderator 
Therapeutic Targeting of ATR Yields Durable Regressions in Small Cell Lung Cancers with High Replication Stress  13:20  Anish Thomas 
Molecular Subtyping of Primary SCLC Tumors and the Associations between Molecular Subtypes and Therapeutic Biomarkers  13:32 Haobin Chen
Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small-cell Lung Cancer 13:44  Ralph Deberardinis
Ferroptosis in SCLC 13:56 Siliva Von Karstedt 
Panel Discussion with Q&A  14:08   

All Times in ET

Mouse Models (Xenografts and GEMMs)

Presentation  Start Time Presenter
Session Welcome    Roman Thomas, Session Moderator 
Metastasis in SCLC 14:30  Arnaud Augert 
Chemoresistance and co Clinical Trials  14:42 Ben Drapkin 
Uncovering Chemoradiation Resistance Mechanisms in Limited Stage SCLC using a paired PDX-PDO-ODX Platform 14:54 Christine Hann 
GEMM of LUAD to SCLC  15:06  Eric Gardner
Panel Discussion with Q&A  15:18  

All Times in ET

 Immunotherapy Approaches in SCLC 

Presentation  Start Time Presenter 
Session Welcome   Ticiana Leal, Session Moderator 
EZH2 in SCLC  15:40  David Barbie 
NK cells in SCLC   15:52 Kate Sutherland
Anti-tumor and Immunological Effects of CDK Inhibitors in SCLC  16:04  Kwok Wong
Examining Predictors of Response to Immune Checkpoint Blockade in SCLC 16:16  Nitin Roper
Panel Discussion with Q&A  16:28   

All Times in ET

Day Two Closing 

Presentation  Start Time Presenter
Closing Message 16:50  Charles Rudin and Triparna Sen, Meeting Chairs

 

All Times in ET

Industry Symposium 

Session Start Time 
October 30 Industry Symposium 17:05 

Share

Meeting Chairs

Triparna Sen
Triparna Sen, PhD

PhD

Assistant Attending in the Department of Medicine
Memorial Sloan Kettering Cancer Center
Headshot of Dr. Rudin
Charles M. Rudin

MD, PhD

Medical Oncologist
Memorial Sloan Kettering

Interested in advertising and exhibit opportunities?